A multidisciplinary expert panel favoured prostate-specific membrane antigen positron emission tomography/computed tomography for primary staging of unfavourable intermediate- and high-risk prostate cancer and for selecting treatments in metastatic hormone-sensitive prostate cancer. The gene discussed is FOLH1; the disease is Familial prostate cancer.